RecruitingNCT069983685G Cav12 SleepUpdated May 31, 2025

A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans

An interventional study of Nimodipine Capsules and 5G RF-EMF in Mediation of 5G Effects on Sleep, sponsored by Hans-Peter Landolt. Recruiting at 1 site in Switzerland. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Hans-Peter Landolt · Not applicable, Interventional, and Basic science

From the registry’s dates

Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
Registered 6 months after the study started (first participant enrolled Oct 2024, registered Apr 2025).
Started Oct 2024; still recruiting 2 years later.

Phase: Not applicable
Study type: Interventional
Enrollment: 30
Allocation: Randomized
Ages: 20 Years to 40 Years
Sex: All

Study summary

Electromagnetic fields (EMFs) generated by the use of 5G technology influence certain sleep characteristics, especially in individuals carrying a specific genetic variant of a protein in the brain that regulates the activity of nerve cells. This protein is a voltage-gated calcium channel called CaV1.2 and could be involved in the effects of 5G technology on sleep. The calcium channel CaV1.2 can be selectively blocked by the drug nimodipine.

To demonstrate that CaV1.2 is indeed involved in the effects of 5G technology on sleep, the researchers are investigating in this study, with healthy subjects carrying the sought-after genetic variant, whether the administration of nimodipine and thus the blockade of the calcium channel before exposure mitigates or eliminates the effects of EMF on sleep health.

Read the detailed description

This study tests a causal role of voltage-gated CaV1.2 calcium channels in mediating the effects of a 5G electromagnetic field on sleep-related brain health in humans.

The study comprises a large-scale genetic screening in order to select the allele-carriers, a sleep screening night, and four experimental nights where participants are exposed to either an active 5G field or sham, combined with either nimodipine (which is a brain-penetrant L-type calcium channel blocker) or placebo. Participants will undergo polysomnographic recordings, high-density electroencephalography (EEG) during wake, peripheral measurements, cognitive and neuropsychiatric assessments.

Conditions studied

Mediation of 5G Effects on Sleep

Keywords

5G
CACNA1C
CaV1.2
electromagnetic
EMF
nimodipine
RF-EMF
sleep
rs7304986
voltage-gated calcium channel
brain

In context

Lead sponsor

Hans-Peter Landolt is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 20 Years to 40 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the first part of the study (genotyping and questionnaires):

Age: 20-40 years old.
German and/or English language skills (reading and writing)
Informed Consent as documented by signature

For the second and third party of the study:

Completion of the first part of the present study or of the precursor study (BASEC-ID: 2016-02049)
CACNA1C rs7304986 T/C allele-carrier
Male gender
Female gender if using hormonal contraception for the duration of the study (e.g., pill as combination/single preparation, three-month injection, hormonal IUD, hormonal implant, hormonal patch)
Right-handedness
Body Mass Index (BMI): BMI comprised between 17.0 kg/m2 and 26.0 kg/m2
- Moderate alcohol consumption (less than 5 reported alcoholic drinks per week)
- Moderate caffeine consumption (less than 3 reported caffeinated beverage or food products per day such as cola, coffee, energy drinks, green and black tea, chocolate)
- Informed Consent as documented by signature.

Exclusion criteria

Exclusion Criteria:

For the second and third party of the study:

Travel with a time difference of more than 2 time zones in the last 30 days before study entry or during the study period
Shift work at night
Extreme chronotype or duration of sleep (5 hours \< reported habitual sleep duration per night > 10 hours)
Known sleep disorders or diseases
Serious acute or chronic neurological, mental, or general medical conditions that, in the opinion of the investigator, may pose a risk to participation or affect study measurements
Use of medications (regularly or during the study period) that, in the opinion of the investigator, may affect study measurements.
Use of illegal drugs
Smoking (or other tobacco use)
Known or suspected non-compliance with the investigators' indications
Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
Severe skin allergies or hypersensitivities
Participation in another clinical trial in the last 30 days prior to inclusion or during the present study
Contraindications to nimodipine, e.g., known hypersensitivity or allergy to nimodipine or any of the excipients
Other cases in which the use of nimodipine is discouraged according to the summary of product characteristics (SPC)
Women who are pregnant or breast feeding
Intention to become pregnant during the course of the study
Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases (Note: Female participants who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential)
Sleep apnea and nocturnal myoclonus index of ≥ 5 per hour of sleep (as assessed during the screening night)
Sleep efficiency \< 80% (as assessed during the screening night)
Other relevant findings in the screening/adaptation night (e.g., indications of sleep disorders), which in the opinion of the investigator may pose a risk for participation or influence the study measurements.

Study design

Phase: Not applicable
Primary purpose: Basic science
Allocation: Randomized
Intervention model: Crossover assignment
Masking: Double (Participant, Investigator)
Enrollment: 30 participants (estimated)

Study arms

Other
Arm2
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm1
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining eighteen sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm3
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm4
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm6
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm7
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm8
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm9
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm10
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm11
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm12
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm5
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm13
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm14
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm15
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm16
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm17
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm18
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm19
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm20
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm21
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm22
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm23
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF
Other
Arm24
The study includes 24 arms, each corresponding to one of the 24 unique sequences in which the four intervention combinations (drug/placebo × active/sham) can be administered. Given that the expected total sample size is 30 participants, six of these sequences will be randomly assigned to two participants, while the remaining 18 sequences will be assigned to one participant each.
Drug: Nimodipine Capsules · Radiation: 5G RF-EMF

Interventions

DrugNimodipine Capsules
Two times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding.
Radiation5G RF-EMF
Participants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency \[TDD\] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design.

What researchers measure

Primary outcomes

Sleep spindle center frequency
In previous research, the investigators detected a positive shift in the sleep spindle center frequency (during NREM sleep phase) after 30-min pre-sleep exposure to a 5G signal at 3600 MHz, 100 MHz bandwidth in heterozygous T/C allele-carriers (rs7304986) compared to sham. The sleep spindle center frequency is a parameter that can be extracted from the overnight electroencephalographic recordings.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions

Secondary outcomes

Sex distribution of participants
Self-reported biological sex (male or female) is recorded during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Age of Participants
Age is recorded in years based on the year of birth provided during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Pregnancy status
Female participants report current pregnancy status during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
EEG power spectra during Non-Rapid-Eye-Movement (NREM) sleep
Power spectra will be computed from artifact-free EEG data recorded during NREM sleep. Spectral power (µV²/Hz) will be computed in standard frequency bands.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Total sleep time
Sleep electroencephalographic data allow to extract total sleep time (min) (total amount of time spent asleep)
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Neurocognitive performance as assessed in the psychomotor vigilance task (PVT)
The PVT is administered before and after sleep at each experimental night and provides a score reflecting sustained or vigilant attention performance.
Time frame: Assessed on each of the four experimental nights, pre- and post-sleep
Heart rate
Heart rate (bpm) is extracted from electrocardiographic recording during exposure and from polysomnographic overnight recordings
Time frame: Assessed on each of the four experimental nights, from electrocardiographic recordings during pre-sleep exposure and polysomnographic overnight recordings
Handedness of participants
Participants report their handedness (right-handed or left-handed) during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
BMI of participants
Self-reported height (in centimeters) and weight (in kilograms) of participants is reported during the large-scale genetic screening (first study part) via an online questionnaire. From Height and Weight, BMI is calculated.
Time frame: At the large-scale genetic screening
Highest level of education of participants
The highest level of education of participants (elementary school, professional school, high school, university of applied sciences and arts, or university) is self-reported during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Phone call time
Participants report their phone call time without headphones (Not at all, Less than 1 hour per week, 1-2 hours per week or more than 2 hours per week) during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Caffeine consumption
Participants report their caffeine consumption (None, 1-2 caffeinated foods or beverages per day, 3-5 caffeinated foods or beverages per day or More than 5 caffeinated foods or beverages per day) during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Alcohol consumption
Participants report their alcohol consumption (None, Less than 1 glass per week, 1-2 glasses per week, 3-5 glasses per week or More than 5 glasses per week) during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Electrohypersensitivity (EHS) status
Participants report their EHS status during the large-scale genetic screening (first study part) via filling out the online questionnaire by M. Röösli, E. Mohler, and P. Frei (2010).
Time frame: At the large-scale genetic screening
Sleep disturbances
The presence of sleep disturbances is self-reported by participants during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Comorbidities
Participants self-report the presence of comorbidities during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Night-shift work
Participants report if they engage in night shift work during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Use of medications
Self-reported use of medication is recorded during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Use of illegal drugs
Self-reported use of illegal drugs is recorded during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Use of tobacco products
Use of tobacco products is reported during the large-scale genetic screening (first study part) via an online questionnaire.
Time frame: At the large-scale genetic screening
Subjective sleep quality
Participants report about their subjective sleep quality during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index" (high global PSQI score indicates poor sleep quality).
Time frame: At the large-scale genetic screening
Daytime sleepiness
Participants report about their daytime sleepiness during the large-scale genetic screening (first study part) via filling out the online questionnaire "Epworth Sleepiness Scale " (high ESS score indicates high daytime sleepiness).
Time frame: At the large-scale genetic screening
Diurnal preference
Participants report about their diurnal preference during the large-scale genetic screening (first study part) via filling out the online questionnaire "Munich Chronotype Questionnaire" (if the mid-sleep time on the MCTQ is earlier than 04:00, the participant is considered as preferential morning type, otherwise as preferential evening type).
Time frame: At the large-scale genetic screening
Habitual bedtime
Participants report about their subjective habitual bedtime (hh:mm) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Time frame: At the large-scale genetic screening
Habitual rise time
Participants report about their subjective habitual rise time (hh:mm) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Time frame: At the large-scale genetic screening
Reported time to fall asleep
Participants report about their subjective time to fall asleep (min) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Time frame: At the large-scale genetic screening
Reported sleep duration
Participants report about their subjective sleep duration (h:mm) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Pittsburgh Sleep Quality Index".
Time frame: At the large-scale genetic screening
Positive and Negative Affect Schedule
Participants report about positive and negative feelings (over the last 12 months) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Positive and Negative Affect Schedule".
Time frame: At the large-scale genetic screening
Nocturnal mentation
Participants report about their nocturnal mentation during the large-scale genetic screening (first study part) via filling out online the "Dream Thought Questionnaire".
Time frame: At the large-scale genetic screening
Depressive tendency
Participants report about their depressive-like symptoms (experienced in the last 2 weeks) during the large-scale genetic screening (first study part) via filling out the online questionnaire "Beck Depression Index II (BDI-II)".
Time frame: At the large-scale genetic screening
Mental suggestibility tendency
Participants report about their mental suggestibility tendency during the large-scale genetic screening (first study part) via filling out the online questionnaire "Short Suggestibility Scale".
Time frame: At the large-scale genetic screening
Schizotypal tendency
Participants report about their schizotypal tendencies during the large-scale genetic screening (first study part) via filling out an online adaptation of the questionnaire "Magical Ideation Scale (MIS)".
Time frame: At the large-scale genetic screening
ADHD tendency
Participants report about their ADHD-like symptoms during the large-scale genetic screening (first study part) via filling out the online questionnaire "Adult ADHD Self-Report Scale v1.1 (ASRS)".
Time frame: At the large-scale genetic screening
EEG power spectra during wakefulness
Power spectra will be computed from artifact-free EEG data recorded during wakefulness. Spectral power (µV²/Hz) will be computed in standard frequency bands.
Time frame: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
EEG power spectra during Rapid Eye Movement (REM) sleep
Power spectra will be computed from artifact-free EEG data recorded during REM sleep. Spectral power (µV²/Hz) will be computed in standard frequency bands.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during NREM sleep
The NREM sleep power spectra will be used to extract and parametrize the aperiodic component.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during REM sleep
The REM sleep power spectra will be used to extract and parametrize the aperiodic component.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Aperiodic component of the EEG power spectrum during wakefulness
The wake power spectra will be used to extract and parametrize the aperiodic component.
Time frame: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
Periodic component of the EEG power spectrum during NREM sleep
Gaussian peaks detected in the NREM sleep power spectrum will be used to extract the periodic components, including center frequency, power, and bandwidth.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Periodic component of the EEG power spectrum during REM sleep
Gaussian peaks detected in the REM sleep power spectrum will be used to extract the periodic components, including center frequency, power, and bandwidth.
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions.
Periodic component of the EEG power spectrum during wakefulness
Gaussian peaks detected in the wake power spectrum will be used to extract the periodic components, including center frequency, power, and bandwidth.
Time frame: Assessed on each of the four experimental nights, from pre- and post-sleep wake electroencephalographic recordings
Sleep efficiency
Sleep electroencephalographic data allow to extract sleep efficiency (%) ((total sleep time/time in bed) \* 100)
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Sleep latency
Sleep electroencephalographic data allow to extract sleep latency (time between lights-off and first occurrence of NREM sleep stage N2).
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions.
Wakefulness after sleep onset
Sleep electroencephalographic data allow to extract WASO (min) (wakefulness after sleep onset).
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Time spent in the different sleep stages
Sleep electroencelographic data allow to calculate the time (min) spent in each sleep substage (NREM1, NREM2, NREM3, REM).
Time frame: Assessed on each of the four experimental nights, from overnight electroencephalographic recordings following randomized combinations of drug (nimodipine or placebo) and RF-EMF exposure (5G or sham), with a minimum of 3 days washout between sessions
Neurocognitive performance as assessed in the sequential finger tapping task (FTT)
The FTT is administered before and after sleep at each experimental night and provides a score reflecting procedural memory and learning performance.
Time frame: Assessed on each of the four experimental nights, pre- and post-sleep
Neurocognitive performance as assessed in the visuospatial 2D Object Location Task (OLT)
The OLT is administered before and after sleep at each experimental night and provides a score reflecting declarative memory and learning performance.
Time frame: Assessed on each of the four experimental nights, pre- and post-sleep
Heart rate variability
Heart rate variability is extracted from electrocardiographic recording during exposure and from polysomnographic overnight recordings.
Time frame: Assessed on each of the four experimental nights, from electrocardiographic recordings during pre-sleep exposure and polysomnographic overnight recordings
Pupil size
Pupil size variation is recorded during exposure.
Time frame: Assessed on each of the four experimental nights, from pupillometry recordings during pre-sleep exposure.

Study locations

1 of 1 sites recruiting

University of Zurich, Institute of Pharmacology and Toxicology
Zurich, Canton of Zurich 8057, Switzerland
- Rachele Maria D'Angelo, M. Sc. · Contact · rachele.dangelo@pharma.uzh.ch · +41 44 635 59 61
- Hans-Peter Landolt, Prof. Dr. sc. nat. · Contact · landolt@pharma.uzh.ch · +41 44 635 59 53
- Rachele Maria D'Angelo, M.Sc. · Sub investigator
- Hans-Peter Landolt, Prof. Dr. sc. nat. · Principal investigator
- Banjamin Stucki, Dr. · Sub investigator
- Corinne Eicher, M. D. · Sub investigator
Recruiting

References and documents

Individual participant data

Plan to share: No — Any disclosure of information to individuals not directly involved in the study must be approved by the owner of the data.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06998368
Lead sponsor: Hans-Peter Landolt
Collaborators: Federal Office for the Environment, Switzerland
Responsible party: Hans-Peter Landolt (Prof. Dr. sc. nat., University of Zurich) — Sponsor-investigator
First posted: May 31, 2025
Start date: Oct 22, 2024
Primary completion: Jun 2026 (estimated)
Completion: Dec 2026 (estimated)
Last update: May 31, 2025

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nimodipine

Other studies from this sponsor

Hans-Peter Landolt

The Role of the LC-NA System in Experimental Sleep FragmentationRecruitingNCT07167316Phase 1

Start the discussion